论文部分内容阅读
利什曼病是一种由利什曼原虫(Leishmania spp)引起的虫媒疾病。皮肤利什曼病(CL)表现为原发性皮肤溃疡,一般不产生内脏病变,主要流行于中东和北非一些国家。目前,CL尚无有效的预防性或治疗性疫苗,病情也无法得到控制。虽然大多数的CL人畜共患患者可在6~9个月内愈合,但患者身上会留下大面积终生性疤痕。治疗利什曼病的一线药物锑剂具有毒性,且反复注射给患者带来严重的疼痛毒副作用。最近,在伊朗有报道指出,CL对锑剂逐步产生耐药性,这迫使研究人员尽快开发出新的治疗方法。人中性粒细胞肽-1(HNP-1)为一种具有广泛抗菌活性的防御素类物质。HNP-1天然存在于嗜中性粒细胞颗粒内,该细胞具有杀灭利什曼原虫寄生的能力,并可作为宿主细胞。伊朗Pasteur研究所的工作人员利用原核表
Leishmaniasis is an insect disease caused by Leishmania spp. Cutaneous leishmaniasis (CL) showed primary skin ulcers, generally do not produce visceral lesions, mainly in the Middle East and North Africa in some countries. At present, there is no effective preventive or therapeutic vaccine for CL and the condition can not be controlled. Although most CL zoonotic patients can heal within 6 to 9 months, large permanent scarring may persist in the patient. The first-line antimony agent for the treatment of leishmaniasis is toxic and repeated injections cause severe pain and side effects. Recently, it has been reported in Iran that CL is gradually developing resistance to antimony agents, forcing researchers to develop new treatments as soon as possible. Human neutrophil peptide-1 (HNP-1) is a defensin with broad antimicrobial activity. HNP-1 is naturally found in neutrophil granules, which have the ability to kill Leishmania parasites and act as host cells. Staff at Iran's Pasteur Institute make use of prokaryotic tables